• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Mol Sci. Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using C

tetano

Editor, Senior Moderator
Int J Mol Sci. 2020 Apr 8;21(7). pii: E2574. doi: 10.3390/ijms21072574.
Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.


Yip CC[SUP]1[/SUP], Ho CC[SUP]2[/SUP], Chan JF[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5,[/SUP][SUP]6[/SUP], To KK[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5,[/SUP][SUP]6[/SUP], Chan HS[SUP]7[/SUP], Wong SC[SUP]8[/SUP], Leung KH[SUP]4[/SUP], Fung AY[SUP]4[/SUP], Ng AC[SUP]4[/SUP], Zou Z[SUP]4[/SUP], Tam AR[SUP]9[/SUP], Chung TW[SUP]1[/SUP], Chan KH[SUP]3,[/SUP][SUP]4,[/SUP][SUP]6[/SUP], **** IF[SUP]10[/SUP], Cheng VC[SUP]1[/SUP], Tsang OT[SUP]11[/SUP], Tsui SKW[SUP]12[/SUP], Yuen KY[SUP]3,[/SUP][SUP]4,[/SUP][SUP]5,[/SUP][SUP]6[/SUP].

Author information




Abstract

The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID[SUB]50[/SUB]/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed.



KEYWORDS:

COVID-19; COVID-19-nsp2 assay; GolayMetaMiner; SARS-CoV-2; clinical evaluation; genome subtraction; nsp2; real-time RT-PCR; sensitivity; specificity


PMID:32276333DOI:10.3390/ijms21072574
Free full text
 
Back
Top